Summary

The global Antibody-drug Conjugates (ADCs) CMO and CDMO market size is predicted to grow from US$ 4422 million in 2025 to US$ 13010 million in 2031; it is expected to grow at a CAGR of 19.7% from 2025 to 2031.
Antibody-drug conjugates (ADCs) are a type of targeted biologics that connect cytotoxic drugs to monoclonal antibodies through linkers, which can be efficiently transported to target tumor cells to exert anti-tumor effects. CMO and CDMO companies specialize in drug production services, with a main focus on customized production during drug research and development and commercial production after market launch.
United States market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Antibody-drug Conjugates (ADCs) CMO and CDMO is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Antibody-drug Conjugates (ADCs) CMO and CDMO players cover Lonza Group, Merck KGaA, WuXi XDC, Abbvie, Piramal Pharma Solutions, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Antibody-drug Conjugates (ADCs) CMO and CDMO Industry Forecast” looks at past sales and reviews total world Antibody-drug Conjugates (ADCs) CMO and CDMO sales in 2024, providing a comprehensive analysis by region and market sector of projected Antibody-drug Conjugates (ADCs) CMO and CDMO sales for 2025 through 2031. With Antibody-drug Conjugates (ADCs) CMO and CDMO sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Antibody-drug Conjugates (ADCs) CMO and CDMO industry.
This Insight Report provides a comprehensive analysis of the global Antibody-drug Conjugates (ADCs) CMO and CDMO landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Antibody-drug Conjugates (ADCs) CMO and CDMO portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Antibody-drug Conjugates (ADCs) CMO and CDMO market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Antibody-drug Conjugates (ADCs) CMO and CDMO and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Antibody-drug Conjugates (ADCs) CMO and CDMO.
This report presents a comprehensive overview, market shares, and growth opportunities of Antibody-drug Conjugates (ADCs) CMO and CDMO market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cleavable linkers
Non-cleavable linkers
Segmentation by Application:
Solid Tumors
Hematological Malignanciesncies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Lonza Group
Merck KGaA
WuXi XDC
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Axplora
Aji Bio-Pharma
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
TOT Biopharm
Huadong Medicine
Innovent Biologics
Shanghai Henlius Biotech

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size (2020-2031)
2.1.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Antibody-drug Conjugates (ADCs) CMO and CDMO by Country/Region (2020, 2024 & 2031)
2.2 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Type
2.2.1 Cleavable linkers
2.2.2 Non-cleavable linkers
2.3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type
2.3.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
2.4 Antibody-drug Conjugates (ADCs) CMO and CDMO Segment by Application
2.4.1 Solid Tumors
2.4.2 Hematological Malignanciesncies
2.5 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application
2.5.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
3 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Player
3.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Player
3.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Player (2020-2025)
3.1.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Player (2020-2025)
3.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Antibody-drug Conjugates (ADCs) CMO and CDMO by Region
4.1 Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
4.2 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Annual Revenue by Country/Region (2020-2025)
4.3 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth (2020-2025)
4.4 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth (2020-2025)
4.5 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth (2020-2025)
4.6 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth (2020-2025)
5 Americas
5.1 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
5.2 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
5.3 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025)
6.2 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
6.3 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025)
7.2 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
7.3 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO by Region (2020-2025)
8.2 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025)
8.3 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast
10.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Region (2026-2031)
10.1.1 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Region (2026-2031)
10.1.2 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.1.3 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.1.4 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.1.5 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.2 Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Country (2026-2031)
10.2.1 United States Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.2.2 Canada Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.2.3 Mexico Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.2.4 Brazil Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.3 APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Region (2026-2031)
10.3.1 China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Forecast
10.3.2 Japan Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.3.3 Korea Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.3.4 Southeast Asia Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.3.5 India Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.3.6 Australia Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.4 Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Country (2026-2031)
10.4.1 Germany Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.4.2 France Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.4.3 UK Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.4.4 Italy Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.4.5 Russia Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.5 Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Region (2026-2031)
10.5.1 Egypt Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.5.2 South Africa Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.5.3 Israel Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.5.4 Turkey Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
10.6 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Type (2026-2031)
10.7 Global Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Antibody-drug Conjugates (ADCs) CMO and CDMO Forecast
11 Key Players Analysis
11.1 Lonza Group
11.1.1 Lonza Group Company Information
11.1.2 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.1.3 Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Lonza Group Main Business Overview
11.1.5 Lonza Group Latest Developments
11.2 Merck KGaA
11.2.1 Merck KGaA Company Information
11.2.2 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.2.3 Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Merck KGaA Main Business Overview
11.2.5 Merck KGaA Latest Developments
11.3 WuXi XDC
11.3.1 WuXi XDC Company Information
11.3.2 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.3.3 WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 WuXi XDC Main Business Overview
11.3.5 WuXi XDC Latest Developments
11.4 Abbvie
11.4.1 Abbvie Company Information
11.4.2 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.4.3 Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Abbvie Main Business Overview
11.4.5 Abbvie Latest Developments
11.5 Piramal Pharma Solutions
11.5.1 Piramal Pharma Solutions Company Information
11.5.2 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.5.3 Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Piramal Pharma Solutions Main Business Overview
11.5.5 Piramal Pharma Solutions Latest Developments
11.6 Catalent
11.6.1 Catalent Company Information
11.6.2 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.6.3 Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Catalent Main Business Overview
11.6.5 Catalent Latest Developments
11.7 Sterling Pharma Solutions
11.7.1 Sterling Pharma Solutions Company Information
11.7.2 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.7.3 Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Sterling Pharma Solutions Main Business Overview
11.7.5 Sterling Pharma Solutions Latest Developments
11.8 Axplora
11.8.1 Axplora Company Information
11.8.2 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.8.3 Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Axplora Main Business Overview
11.8.5 Axplora Latest Developments
11.9 Aji Bio-Pharma
11.9.1 Aji Bio-Pharma Company Information
11.9.2 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.9.3 Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Aji Bio-Pharma Main Business Overview
11.9.5 Aji Bio-Pharma Latest Developments
11.10 BSP Pharmaceuticals
11.10.1 BSP Pharmaceuticals Company Information
11.10.2 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.10.3 BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 BSP Pharmaceuticals Main Business Overview
11.10.5 BSP Pharmaceuticals Latest Developments
11.11 Cerbios-Pharma
11.11.1 Cerbios-Pharma Company Information
11.11.2 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.11.3 Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Cerbios-Pharma Main Business Overview
11.11.5 Cerbios-Pharma Latest Developments
11.12 Goodwin Biotechnology
11.12.1 Goodwin Biotechnology Company Information
11.12.2 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.12.3 Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 Goodwin Biotechnology Main Business Overview
11.12.5 Goodwin Biotechnology Latest Developments
11.13 TOT Biopharm
11.13.1 TOT Biopharm Company Information
11.13.2 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.13.3 TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.13.4 TOT Biopharm Main Business Overview
11.13.5 TOT Biopharm Latest Developments
11.14 Huadong Medicine
11.14.1 Huadong Medicine Company Information
11.14.2 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.14.3 Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.14.4 Huadong Medicine Main Business Overview
11.14.5 Huadong Medicine Latest Developments
11.15 Innovent Biologics
11.15.1 Innovent Biologics Company Information
11.15.2 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.15.3 Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.15.4 Innovent Biologics Main Business Overview
11.15.5 Innovent Biologics Latest Developments
11.16 Shanghai Henlius Biotech
11.16.1 Shanghai Henlius Biotech Company Information
11.16.2 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
11.16.3 Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue, Gross Margin and Market Share (2020-2025)
11.16.4 Shanghai Henlius Biotech Main Business Overview
11.16.5 Shanghai Henlius Biotech Latest Developments
12 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Region (2020 VS 2024 VS 2031) & ($ millions)
Table 2. Antibody-drug Conjugates (ADCs) CMO and CDMO Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Cleavable linkers
Table 4. Major Players of Non-cleavable linkers
Table 5. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Type (2020 VS 2024 VS 2031) & ($ millions)
Table 6. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & ($ millions)
Table 7. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
Table 8. Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size CAGR by Application (2020 VS 2024 VS 2031) & ($ millions)
Table 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & ($ millions)
Table 10. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
Table 11. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Player (2020-2025) & ($ millions)
Table 12. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Player (2020-2025)
Table 13. Antibody-drug Conjugates (ADCs) CMO and CDMO Key Players Head office and Products Offered
Table 14. Antibody-drug Conjugates (ADCs) CMO and CDMO Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & ($ millions)
Table 18. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Region (2020-2025)
Table 19. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue by Country/Region (2020-2025) & ($ millions)
Table 20. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Country/Region (2020-2025)
Table 21. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & ($ millions)
Table 22. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Country (2020-2025)
Table 23. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & ($ millions)
Table 24. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
Table 25. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & ($ millions)
Table 26. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
Table 27. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & ($ millions)
Table 28. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Region (2020-2025)
Table 29. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & ($ millions)
Table 30. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & ($ millions)
Table 31. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Country (2020-2025) & ($ millions)
Table 32. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Country (2020-2025)
Table 33. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & ($ millions)
Table 34. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & ($ millions)
Table 35. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Region (2020-2025) & ($ millions)
Table 36. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Type (2020-2025) & ($ millions)
Table 37. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size by Application (2020-2025) & ($ millions)
Table 38. Key Market Drivers & Growth Opportunities of Antibody-drug Conjugates (ADCs) CMO and CDMO
Table 39. Key Market Challenges & Risks of Antibody-drug Conjugates (ADCs) CMO and CDMO
Table 40. Key Industry Trends of Antibody-drug Conjugates (ADCs) CMO and CDMO
Table 41. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Region (2026-2031) & ($ millions)
Table 42. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share Forecast by Region (2026-2031)
Table 43. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Type (2026-2031) & ($ millions)
Table 44. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Forecast by Application (2026-2031) & ($ millions)
Table 45. Lonza Group Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 46. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 47. Lonza Group Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 48. Lonza Group Main Business
Table 49. Lonza Group Latest Developments
Table 50. Merck KGaA Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 51. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 52. Merck KGaA Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 53. Merck KGaA Main Business
Table 54. Merck KGaA Latest Developments
Table 55. WuXi XDC Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 56. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 57. WuXi XDC Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 58. WuXi XDC Main Business
Table 59. WuXi XDC Latest Developments
Table 60. Abbvie Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 61. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 62. Abbvie Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 63. Abbvie Main Business
Table 64. Abbvie Latest Developments
Table 65. Piramal Pharma Solutions Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 66. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 67. Piramal Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 68. Piramal Pharma Solutions Main Business
Table 69. Piramal Pharma Solutions Latest Developments
Table 70. Catalent Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 71. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 72. Catalent Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 73. Catalent Main Business
Table 74. Catalent Latest Developments
Table 75. Sterling Pharma Solutions Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 76. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 77. Sterling Pharma Solutions Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 78. Sterling Pharma Solutions Main Business
Table 79. Sterling Pharma Solutions Latest Developments
Table 80. Axplora Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 81. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 82. Axplora Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 83. Axplora Main Business
Table 84. Axplora Latest Developments
Table 85. Aji Bio-Pharma Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 86. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 87. Aji Bio-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 88. Aji Bio-Pharma Main Business
Table 89. Aji Bio-Pharma Latest Developments
Table 90. BSP Pharmaceuticals Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 91. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 92. BSP Pharmaceuticals Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 93. BSP Pharmaceuticals Main Business
Table 94. BSP Pharmaceuticals Latest Developments
Table 95. Cerbios-Pharma Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 96. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 97. Cerbios-Pharma Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 98. Cerbios-Pharma Main Business
Table 99. Cerbios-Pharma Latest Developments
Table 100. Goodwin Biotechnology Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 101. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 102. Goodwin Biotechnology Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 103. Goodwin Biotechnology Main Business
Table 104. Goodwin Biotechnology Latest Developments
Table 105. TOT Biopharm Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 106. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 107. TOT Biopharm Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 108. TOT Biopharm Main Business
Table 109. TOT Biopharm Latest Developments
Table 110. Huadong Medicine Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 111. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 112. Huadong Medicine Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 113. Huadong Medicine Main Business
Table 114. Huadong Medicine Latest Developments
Table 115. Innovent Biologics Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 116. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 117. Innovent Biologics Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 118. Innovent Biologics Main Business
Table 119. Innovent Biologics Latest Developments
Table 120. Shanghai Henlius Biotech Details, Company Type, Antibody-drug Conjugates (ADCs) CMO and CDMO Area Served and Its Competitors
Table 121. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Product Offered
Table 122. Shanghai Henlius Biotech Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue ($ million), Gross Margin and Market Share (2020-2025)
Table 123. Shanghai Henlius Biotech Main Business
Table 124. Shanghai Henlius Biotech Latest Developments


List of Figures
Figure 1. Antibody-drug Conjugates (ADCs) CMO and CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth Rate (2020-2031) ($ millions)
Figure 6. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 7. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country/Region (2024)
Figure 8. Antibody-drug Conjugates (ADCs) CMO and CDMO Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 9. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type in 2024
Figure 10. Antibody-drug Conjugates (ADCs) CMO and CDMO in Solid Tumors
Figure 11. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market: Solid Tumors (2020-2025) & ($ millions)
Figure 12. Antibody-drug Conjugates (ADCs) CMO and CDMO in Hematological Malignanciesncies
Figure 13. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market: Hematological Malignanciesncies (2020-2025) & ($ millions)
Figure 14. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application in 2024
Figure 15. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Revenue Market Share by Player in 2024
Figure 16. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Region (2020-2025)
Figure 17. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2020-2025 ($ millions)
Figure 18. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2020-2025 ($ millions)
Figure 19. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2020-2025 ($ millions)
Figure 20. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2020-2025 ($ millions)
Figure 21. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Value Market Share by Country in 2024
Figure 22. United States Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 23. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 24. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 25. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 26. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Region in 2024
Figure 27. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
Figure 28. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
Figure 29. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 30. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 31. South Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 32. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 33. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 34. Australia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 35. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Country in 2024
Figure 36. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
Figure 37. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
Figure 38. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 39. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 40. UK Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 41. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 42. Russia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 43. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Region (2020-2025)
Figure 44. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Type (2020-2025)
Figure 45. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share by Application (2020-2025)
Figure 46. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 47. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 48. Israel Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 49. Turkey Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 50. GCC Countries Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Growth 2020-2025 ($ millions)
Figure 51. Americas Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 52. APAC Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 53. Europe Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 54. Middle East & Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 55. United States Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 56. Canada Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 57. Mexico Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 58. Brazil Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 59. China Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 60. Japan Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 61. Korea Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 62. Southeast Asia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 63. India Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 64. Australia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 65. Germany Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 66. France Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 67. UK Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 68. Italy Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 69. Russia Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 70. Egypt Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 71. South Africa Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 72. Israel Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 73. Turkey Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)
Figure 74. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share Forecast by Type (2026-2031)
Figure 75. Global Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size Market Share Forecast by Application (2026-2031)
Figure 76. GCC Countries Antibody-drug Conjugates (ADCs) CMO and CDMO Market Size 2026-2031 ($ millions)